Welcome to our dedicated page for Xortx Therapeutics news (Ticker: XRTX), a resource for investors and traders seeking the latest updates and insights on Xortx Therapeutics stock.
XORTX Therapeutics Inc (XRTX) is a clinical-stage biopharmaceutical company advancing therapies for progressive kidney diseases and metabolic disorders. This page serves as the definitive source for verified news, press releases, and regulatory updates related to XRTX's research and strategic initiatives.
Key resources include: Clinical trial developments for conditions like diabetic nephropathy and polycystic kidney disease, partnership announcements with pharmaceutical collaborators, and regulatory milestones. Investors and researchers will find timely updates on xanthine oxidase inhibitor research and uric acid modulation therapies.
Content spans therapeutic advancements, intellectual property updates, and analysis of metabolic disorder treatments. Bookmark this page for structured access to XRTX's progress in addressing complex renal health challenges through evidence-based biopharmaceutical innovation.
XORTX Therapeutics announced the repricing of warrants issued in October 2021, receiving approval from the TSX Venture Exchange to amend the terms. The repricing affects 101,111 warrants post a 9:1 consolidation, lowering the exercise price from USD $42.93 to USD $5.00. If the company's stock price exceeds USD $6.50 for ten consecutive trading days, warrant holders must exercise their options within 30 days or face expiration.
XORTX Therapeutics Inc. announces the amendment of 1,024,099 outstanding common share purchase warrants by changing the exercise price to USD $5.00 per share. The TSX Venture Exchange approved the amendments related to Private Placements from 2021 to 2022. Additionally, a new Warrant Acceleration Provision was introduced.
FAQ
What is the current stock price of Xortx Therapeutics (XRTX)?
What is the market cap of Xortx Therapeutics (XRTX)?
